AssetMark Inc’s Acadia Pharmaceuticals ACAD Stock Holding History

AssetMark Inc’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$8.73K	Buy	345 +100	+41%	+$2.2K	﹤0.01%	2503
2026 Q1	$5.45K	Buy	245 +23	+10%	+$550	﹤0.01%	2531
2025 Q4	$5.93K	Buy	222 +25	+13%	+$597	﹤0.01%	2409
2025 Q3	$4.2K	Buy	197 +169	+604%	+$4K	﹤0.01%	2401
2025 Q2	$604	Sell	28 -9	-24%	-$167	﹤0.01%	2711
2025 Q1	$615	Hold	37	–	–	﹤0.01%	2378
2024 Q4	$679	Buy	+37	New	+$597	﹤0.01%	2325
2016 Q1	–	Sell	-15	Closed	-$1K	–	1163
2015 Q4	$1K	Buy	+15	New	+$528	﹤0.01%	1156

Other funds holding ACAD

Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Nordea Investment Management Stockholm, Sweden $123B AUM 38.85% 1-Year Est. Return

ALPS Advisors Denver, Colorado $21.3B AUM 23.41% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Envestnet Asset Management Chicago, Illinois $424B AUM 22.94% 1-Year Est. Return

New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return

AssetMark Inc's ACAD Position: Q2 2026 in Review

AssetMark Inc increased its Acadia Pharmaceuticals (ACAD) stake by 41% in Q2 2026, buying an estimated $2.2K and bringing the position to 345 shares worth $8.73K. The position accounts for ﹤0.01% of the portfolio, ranked #2503.

AssetMark Inc first reported a position in ACAD in Q4 2015 and has held it in 8 quarters since. 102 funds tracked by Wall St. Rank hold ACAD as of Q2 2026.

AssetMark Inc held 345 shares of Acadia Pharmaceuticals worth $8.73K as of Q2 2026.
AssetMark Inc bought 100 Acadia Pharmaceuticals shares in Q2 2026, an estimated $2.2K.
Acadia Pharmaceuticals made up ﹤0.01% of AssetMark Inc's portfolio in Q2 2026, its #2503 holding.
AssetMark Inc first reported a position in Acadia Pharmaceuticals in Q4 2015 and has held it in 8 quarters since.
102 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2026.

Based on AssetMark Inc's 13F filing for Q2 2026, filed 30 Jul 2026.